866-997-4948(US-Canada Toll Free)

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 136 Pages

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease Pipeline Review, H2 2016, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 9, 4, 1, 6, 2 and 1 respectively.

Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Anemia in Chronic Kidney Disease (Renal Anemia) Overview 10
Therapeutics Development 11
Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview 11
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies 12
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies 19
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development 22
3SBio Inc 22
Acceleron Pharma Inc 23
Aevi Genomic Medicine Inc 24
Akebia Therapeutics Inc 25
Amgen Inc 26
Bayer AG 27
Biocad 28
CCM Duopharma Biotech Bhd 29
Chong Kun Dang Pharmaceutical Corp 30
CJ HealthCare Corp 31
Daiichi Sankyo Company Ltd 32
Dong-A Socio Holdings Co Ltd 33
Dr. Reddy's Laboratories Ltd 34
FibroGen Inc 35
GlaxoSmithKline Plc 36
Intas Pharmaceuticals Ltd 37
Japan Tobacco Inc 38
JCR Pharmaceuticals Co Ltd 39
Jiangsu Hansoh Pharmaceutical Co Ltd 40
LG Life Science LTD 41
Myungmoon pharmaceutical Co Ltd 42
Panacea Biotec Ltd 43
Pfizer Inc 44
PharmaEssentia Corp 45
PhytoHealth Corp 46
Pieris Pharmaceuticals Inc 47
Reliance Life Sciences Pvt Ltd 48
Sandoz International GmbH 49
Zydus Cadila Healthcare Ltd 50
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
daprodustat - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
darbepoetin alfa - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
darbepoetin alfa - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
darbepoetin alfa - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
darbepoetin alfa - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
darbepoetin alfa - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
darbepoetin alfa - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
darbepoetin alfa - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
darbepoetin alfa - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
darbepoetin alfa - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
darbepoetin alfa - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
DS-1093 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
EPO-018B - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
epoetin alfa - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
epoetin alfa - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
epoetin zeta - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
erythropoietin - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
FG-2216 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
HSA-EPO - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
JTZ-951 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
LBDE - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
MDGN-201 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
MMP-0101 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
molidustat - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
PEG-EPO - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Peg-EPO - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
PEG-EPO - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
pegylated erythropoietin - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
PHEP-01 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
PRS-080 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Recombinant Protein for Renal Anemia - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
roxadustat - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
sotatercept - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
SSS-06 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
SSS-17 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
vadadustat - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects 121
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products 122
Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones 123
Featured News & Press Releases 123
Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease 123
Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia 123
Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease 124
Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients 125
Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131) 126
Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease 126
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 126
Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment 128
May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction 128
May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat 129
Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings 130
Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication 130
Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat 131
Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustats Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease 131
Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program 133
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136

List of Tables
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H2 2016 22
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Acceleron Pharma Inc, H2 2016 23
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H2 2016 24
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H2 2016 25
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H2 2016 26
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H2 2016 27
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H2 2016 28
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H2 2016 29
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 30
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H2 2016 31
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 32
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 33
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 34
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H2 2016 35
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H2 2016 36
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H2 2016 37
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H2 2016 38
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H2 2016 39
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 40
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by LG Life Science LTD, H2 2016 41
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2016 42
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H2 2016 43
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H2 2016 44
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H2 2016 45
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H2 2016 46
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 47
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016 48
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Sandoz International GmbH, H2 2016 49
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 50
Assessment by Monotherapy Products, H2 2016 51
Number of Products by Stage and Target, H2 2016 53
Number of Products by Stage and Mechanism of Action, H2 2016 55
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H2 2016 121
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H2 2016 12

List of Figures
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 51
Number of Products by Targets, H2 2016 52
Number of Products by Stage and Targets, H2 2016 52
Number of Products by Mechanism of Actions, H2 2016 54
Number of Products by Stage and Mechanism of Actions, H2 2016 54
Number of Products by Routes of Administration, H2 2016 56
Number of Products by Stage and Routes of Administration, H2 2016 56
Number of Products by Molecule Types, H2 2016 58
Number of Products by Stage and Molecule Types, H2 2016 58

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *